Literature DB >> 7657063

Fenofibrate: metabolism and species differences for peroxisome proliferation in cultured hepatocytes.

M C Cornu-Chagnon1, H Dupont, A Edgar.   

Abstract

The hypolipidemic agent fenofibrate, which is a peroxisome proliferator in some rodents in vivo, was studied in cultured hepatocytes for its metabolism and effects on enzymatic induction related to peroxisome proliferation so as to lead to a better understanding of the mechanisms involved in peroxisome proliferation. [14C]-Fenofibrate was completely metabolized within 24 hr by primary cultures of rat hepatocytes and the metabolic pattern corresponded to that found in vivo. The main products were fenofibric acid and its glucuronidated form. Carbonyl reduction of fenofibric acid also occurred. The metabolic pattern of [14C]fenofibric acid was nearly the same as that of fenofibrate. Fenofibrate, fenofibric acid, and its reduced metabolite all induced peroxisomal (cyanide-insensitive) palmitoyl-CoA oxidation activity (PCOA) in rat hepatocytes, whereas derivatives lacking the carboxyl group were nearly inactive. The known species differences with respect to sensitivity to peroxisome proliferators in vivo was mirrored in cultured cells because fenofibric acid did not induce peroxisomal PCOA in primary culture of guinea pig hepatocytes nor in the human hepatoma cell line HepG2. The mechanistic association between the induction of CYP4A1-catalyzed lauric acid omega-hydroxylase (LAH) activity and peroxisomal PCOA induction was investigated. Fenofibric acid concomitantly induced LAH activity and peroxisomal PCOA in rat hepatocytes. Specific inhibition of LAH activity (-52%) by 10-undecynoic acid partially prevented induction of peroxisomal PCOA (-32%). The putative role of dicarboxylic acids, the oxidation product of omega-hydroxymonocarboxylic acids, in PCOA induction was further substantiated by the observed induction of peroxisomal PCOA by 1-12-dodecanedioic acid. We conclude that (1) fenofibric acid is the possible proximate peroxisome proliferator of fenofibrate in rat hepatocytes, (2) cultured hepatocytes reflect in vivo sensitivity to fenofibrate with respect to peroxisome proliferation, and (3) there is some evidence that the catalytic activity of the CYP4A1 enzyme mediates, at least in part, peroxisomal PCOA induction.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7657063     DOI: 10.1006/faat.1995.1075

Source DB:  PubMed          Journal:  Fundam Appl Toxicol        ISSN: 0272-0590


  8 in total

1.  Alteration of 20:5n-3 and 22:6n-3 fat contents and liver peroxisomal activities in fenofibrate-treated rainbow trout.

Authors:  Zhen-yu Du; Laurent Demizieux; Pascal Degrace; Joseph Gresti; Bastien Moindrot; Yong-jian Liu; Li-xia Tian; Jun-ming Cao; Pierre Clouet
Journal:  Lipids       Date:  2004-09       Impact factor: 1.880

2.  High glucose potentiates L-FABP mediated fibrate induction of PPARα in mouse hepatocytes.

Authors:  Anca D Petrescu; Avery L McIntosh; Stephen M Storey; Huan Huang; Gregory G Martin; Danilo Landrock; Ann B Kier; Friedhelm Schroeder
Journal:  Biochim Biophys Acta       Date:  2013-06-06

3.  New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

Authors:  A Liu; Y Chen; Z Yang; Y Feng; W Rui; W Luo; Y Liu; F J Gonzalez; R Dai
Journal:  Xenobiotica       Date:  2009-04       Impact factor: 1.908

Review 4.  Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis.

Authors:  Michael K Racke; Anne R Gocke; Mark Muir; Asim Diab; Paul D Drew; Amy E Lovett-Racke
Journal:  J Nutr       Date:  2006-03       Impact factor: 4.798

Review 5.  The PPARα-dependent rodent liver tumor response is not relevant to humans: addressing misconceptions.

Authors:  J Christopher Corton; Jeffrey M Peters; James E Klaunig
Journal:  Arch Toxicol       Date:  2017-12-02       Impact factor: 5.153

6.  Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

Authors:  Aiming Liu; Andrew D Patterson; Zongtao Yang; Xinying Zhang; Wei Liu; Fayang Qiu; He Sun; Kristopher W Krausz; Jeffrey R Idle; Frank J Gonzalez; Renke Dai
Journal:  Drug Metab Dispos       Date:  2009-02-27       Impact factor: 3.922

Review 7.  Integrated physiology and systems biology of PPARα.

Authors:  Sander Kersten
Journal:  Mol Metab       Date:  2014-03-06       Impact factor: 7.422

Review 8.  Anticancer Properties of Fenofibrate: A Repurposing Use.

Authors:  Xin Lian; Gang Wang; Honglan Zhou; Zongyu Zheng; Yaowen Fu; Lu Cai
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.